In conclusion, several FLAP antagonists were developed in the last three decades and have been intensively evaluated for the therapy of asthma, COPD, arthritis, and cardiovascular disease in clinics, with partially promising results (Gur et al., 2018a; Prescott et al., 2022). The gene discussed is ALOX5AP; the disease is cardiovascular disorder.